Drug Delivery and Translational Research

CRS members receive a free online subscription   

Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. The journal is published 6 times a year and will be available online to CRS members as part of their annual dues.

Access DDTR Online                Editor-in-Chief Article                Enjoy Articles of DDTR
 

We welcome research focused on the following areas of translational drug delivery research:

  • Designing and developing novel drug delivery systems, with a focus on their application to disease conditions
  • Preclinical and clinical data related to drug delivery systems
  • Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
  • Short-term and long-term biocompatibility of drug delivery systems, host response
  • Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering
  • Image-guided drug therapy
  • Nanomedicine
  • Devices for drug delivery and drug/device combination products

In addition to original full-length papers, communications, and reviews, the journal will also include editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of CRS.

DDTR Research Editors          DDTR Editorial Board

 

Inspirational Note

Dr. Andrew L. Lewis

 Inspirational note by Dr. Andrew L. Lewis

Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery

In this Inspirational Note, Dr. Andrew Lewis and coauthors feature an amazing and innovative discovery that is changing the paradigm of oral peptide delivery.

 

Mansoor Amiji

 Inspirational note by Drs. Lara Milane and Mansoor Amiji

Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine

In this Inspirational Note, Drs. Lara Milane and Mansoor Amiji share their insights and reflections on the impact of the recently approved SARS-CoV-2 mRNA vaccines on the present and future of translational nanomedicines.

 

A. Florence

Inspirational note by Alexander (Sandy) T. Florence  Trajectories in nanotechnology: embracing complexity, seeking analogies

“A timely and truly insightful Inspirational Note by one of the fathers of nanotechnology & pharmaceuticals.”  -Jung Soo Suk, Ph.D., Assistant Professor, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

 

Inspirational Note from Dr. Marianne Ashford, Senior Principal Scientist in Glocal Advanced Drug Delivery Group in Pharmaceutical Sciences at AstraZeneca "Drug delivery - the increasing momentum"  

"In this 'Inspirational Note' you will be inspired by the way industry sees advances in drug delivery and Nanomedicine. Dr. Marianne Ashford talks about the 'increasing momentum'. You should not miss this note if you are interested in translational research." -Prof. Maria José Alonso, Editor-in-Chief of the Drug Delivery and Translational Research (DDTR) Journal, Past President of the Controlled Release Society

Latest Issue of DDTR: June 2021

DDTR June 2021 Journal Cover

 

Best Paper of the June 2021 Issue of DDTRAnti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid.

Summary: Tuberculosis (TB) is one of the ten leading causes of death from communicable diseases worldwide. Acid degradation of rifampicin (RIF) in the presence of isoniazid (INH) is an important factor for its reduced bioavailability and can result in drug-resistant TB. We obtained a new material by loading INH on alginic acid to form a drug-polyelectrolyte complex (AA-INH) that allowed isoniazid release segregation in acid medium. This system, with a very fast delivery system of RIF (CMC-RIF), demonstrated a significant reduction in the degradation product levels, suggesting an improvement in the acid stability of RIF. Furthermore, oral administration to dogs revealed a significant increase in RIF bioavailability. Therefore, CMC-RIF and AA-INH can be prepared using components and methodologies accessible to the health care systems of communities with limited resources and could be useful for the formulation of a solid dosage form to overcome some of the main obstacles in TB treatment.


best

2019 DDTR Best Paper of the Year: Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms

nndd

2019 CRS Nanomedicine and Nanoscale Delivery (NND) Best Paper of the Year: Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses

ordd

2019 DDTR CRS Oral Drug Delivery Focus Group Paper of the Year Award: Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer

Read DDTR's First Inspirational Note: Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men


ISSN: 2190-3948

Editor-in-Chief:
Maria José Alonso, PhD - University of Santiago de Complotela, Spain